Recently, impressive therapeutic successes have been achieved in acute promyelocytic leukemia (APL) exhibiting striking remission rates and long-term survival up to 90%.1 In this, the PML-RARα fusion protein represses the transcription of genes, which are important for myeloid differentiation. The gene discussed is RARA; the disease is acute promyelocytic leukemia.